About Jooho Chung, MD, PhD
Jooho grew up in Ann Arbor, MI. He majored in Applied Mathematics at Harvard College. He received his MD and PhD degrees at the University of Michigan. During his PhD, he investigated the immunobiology of Notch signaling in the setting of T cell alloimmunity, focusing largely on graft-versus-host disease. After graduating from medical school, he did his internship and residency in Internal Medicine at Brigham and Women's Hospital. Subsequently, he completed a fellowship in Adult Hematology/Oncology at the Dana-Farber/Mass General Brigham combined Fellowship. In 2025, he joined the faculty of the Bone Marrow Transplant (BMT) Program at Mass General Cancer Center.
Jooho is a physician-scientist focused on understanding the major mechanisms of immune evasion in hematologic malignancies, pre- and post-allogeneic bone marrow transplantation. He currently lives in Needham, MA with his wife and son.
Departments, Centers, & Programs:
Clinical Interests:
- Acute Leukemia
- Aplastic anemia
- CAR T-cell Therapy
- Hematopoietic Cell Transplantation
- Hodgkin's and Non-Hodgkin's lymphoma
- Multiple myeloma
- Myelodysplastic syndrome (MDS)
- Myeloproliferative neoplasms
Treats:
- Adult
Languages:
- Korean
Locations
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
- MD, University of Michigan
- Fellowship, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Blue Cross Blue Shield
- Harvard Pilgrim Health Care
- Medicaid CT
- Medicare ACO
- Tufts Health Plan
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
I am a laboratory-based physician-scientist with expertise in cancer immunology. My research is currently focused on understanding how hematologic malignancies evade the immune system, with a long-term goal of developing better immune-directed therapeutics. I use unbiased genetic screens in the context of in vitro and in vivo models of anti-leukemic immunity to uncover major mechanisms of immune evasion.